Aeterna Zentaris Announces Closing of US$16.5 Million Public
Offering of Common Shares and Warrants
QUÉBEC CITY, Oct. 17, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced the closing of its previously
announced public offering of 6.6 million units (the
"Offering") generating net proceeds of US$15.2 million, with each unit consisting
of one common share and 0.45 of a warrant to purchase one common
share, at a purchase price of US$2.50
per unit. Each warrant is exercisable for a period of five years at
an exercise price of US$3.45 per
share. Roth Capital Partners, LLC, acted as the sole manager for
the Offering.
The Company intends to use the net proceeds from the Offering to
continue to fund its ongoing drug development activities,
particularly for the continued development of perifosine in
multiple myeloma and the advancement of its AEZS-108 and AEZS-130
programs, as well as for general corporate purposes and working
capital.
This press release does not and shall not constitute an
offer to sell or the solicitation of an offer to buy any of the
Company's securities, nor shall there be any sale of the Company's
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the
regulatory process and general changes in economic conditions.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, unless
required to do so by a governmental authority or by applicable
law.
SOURCE AETERNA ZENTARIS INC.